Project Grant HT94252310529
Award Date
7/1/23
Completion Date
6/30/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
Health Research, Inc. Inc Roswell Park Division Health Research Division (the Division) was awarded a $693,987 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund cancer immunotherapy research from June 1, 2023 through May 31, 2026. Specifically, the Division will investigate strategies to counter solid tumor antigen immune escape using CAR T cell therapies. As a past recipient of Defense Health Agency...
The U.S. Department of Defense's Defense Health Agency awarded Health Research, Inc. a $1,545,300 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING MYCAF-DRIVEN CASTRATION-RESISTANT PROSTATE TUMOR GROWTH." The award, which has a performance period of May 1, 2024 to April 30, 2027, will enable Health Research, Inc.'s Roswell Park Division to perform biomedical research and provide scientific services to advance...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
Health Research, Inc. Roswell Park Division received a $559,647 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research using microfluidic lung cancer models. The two-year award, made on June 1, 2023 and set to conclude on May 31, 2025, will support investigating novel drug resistance mechanisms in lung cancer through "Microfluidic Lung Cancer On A Chip" models. As a past recipient of Defense...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The Department of Defense's Defense Health Agency awarded a $1,301,250 Project Grant to Health Research, Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "INHIBITING MDSC BIOGENESIS TO AUGMENT IMMUNOTHERAPY EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER", will support advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research, conducted at Health Research, Inc.'s Roswell Park...
This Project Grant award of $173,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Health Research, Inc. at Roswell Park in Buffalo, NY to improve the efficacy of chemotherapy for small cell carcinomas of the bladder. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations that address critical health challenges. The award...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $171,700 to Health Research, Inc. to conduct research on the "Mechanism of Anti-SEMA4D Therapy Reversal of Immunosuppression in the Prostate Tumor Microenvironment." The 2-year research project aims to investigate novel cancer immunotherapy approaches to treat prostate cancer. As a non-profit organization, Health Research, Inc. collaborates extensively...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...